RESMED INC (RMD) Stock
RMD has an Alpha Score of 48 out of 100 (weak), computed on Nov 6, 2026 from 3 of 4 sub-scores. 8 members of Congress disclosed 12 trades in RMD since 2017: 3 purchases and 9 sales, most recently Alan Armstrong (purchase, Mar 27, 2026). 6 of the hedge funds AlphaScala tracks reported RMD in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $99.05M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 20.7 and its net margin 26.9% (key statistics as of Nov 4, 2026).
What is RMD's Alpha Score?
How it works →Alpha Score of 48 reflects weak overall profile with moderate momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded RESMED INC (RMD)?
Most recent: Alan Armstrong (purchase, Mar 27, 2026); records start Aug 31, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Kelly Morrison D-MN · House | 2025-06-04 | sale | $1k – $15k |
| Kelly Morrison D-MN · House | 2025-04-28 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-01-13 | sale | $1k – $15k |
| Tommy Tuberville R-AL · Senate | 2024-05-03 | sale | $1k – $15k |
| Peter Meijer R-MI · House | 2021-02-16 | sale | $1k – $15k |
| Tom Carper D-DE · Senate | 2020-07-09 | partial sale | $1k – $15k |
| Tom Carper D-DE · Senate | 2020-04-02 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all RMD political trades →Which hedge funds own RMD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 508K | $99.05M | +53% |
| Millennium Management Israel Englander | 205K | $39.90M | +44% |
| Bridgewater Associates Ray Dalio | 67K | $13.13M | +72% |
| Marshall Wace | 7K | $1.29M | -98% |
| D.E. Shaw David Shaw | 6K | $1.19M | -47% |
| Renaissance Technologies Jim Simons (founder) | 2K | $315.7K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are RESMED INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 23, 26 | Rider Michael J | Global General Counsel | SELL | 400 | $102K |
| Oct 7, 26 | Farrell Michael J. | Chairman and CEO | SELL | 5.0K | $1.1M |
| Sep 8, 26 | Farrell Michael J. | Chairman and CEO | SELL | 5.0K | $1.1M |
| Sep 2, 26 | Farrell Peter C | Director | SELL | 970 | $228K |
| Aug 7, 26 | Farrell Michael J. | Chairman and CEO | SELL | 5.0K | $1.0M |
| Aug 5, 26 | Farrell Peter C | Director | SELL | 8.0K | $1.8M |
| Apr 7, 26 | Farrell Michael J. | Chairman and CEO | SELL | 5.0K | $1.1M |
| Apr 1, 26 | Sandercock Brett | Chief Financial Officer | SELL | 1.0K | $224K |
| Apr 1, 26 | Farrell Peter C | Director | SELL | 2.0K | $450K |
| Mar 9, 26 | Farrell Michael J. | Chairman and CEO | SELL | 5.0K | $1.3M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are RMD's key statistics?
Key statistics as of Nov 4, 2026
How does RMD's valuation compare with the Healthcare sector?
| Metric | RMD | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 20.7 | 28.8 | 111 |
| Net margin | 26.94% | 4.31% | 164 |
| Return on equity | 23.88% | 5.47% | 185 |
| Dividend yield (payers) | 1.25% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
RMD price chart
Powered by TradingViewWhat does RESMED INC do?
ResMed Inc. is a global medical technology company that develops, manufactures, and markets advanced medical devices and cloud-based software solutions for diagnosing, treating, and managing respiratory and sleep disorders. The company operates through two primary segments: Sleep and Breathing Health, and Residential Care Software. Its Sleep and Breathing Health division produces devices including CPAP machines, portable diagnostic tools like ApneaLink Air, masks, and accessories designed for sleep apnea and other respiratory conditions. ResMed's digital health ecosystem spans cloud-connected platforms that enable remote patient monitoring and telemedicine capabilities, providing recurring revenue opportunities through software services. The Residential Care Software segment serves long-term care facilities with specialized management solutions. With a global presence across multiple continents, ResMed addresses the growing healthcare demand for effective sleep and respiratory disorder treatments. The company combines medical device innovation with digital health integration, positioning itself as a leader in improving patient outcomes and supporting healthcare providers worldwide.